Please login to the form below

Not currently logged in
Email:
Password:

Katherine Baicker to join Lilly’s board of directors

Former US government health policy adviser to serve on US pharma company's public policy and compliance committee

Eli Lilly & Company has appointed former health policy adviser to the US government Dr Katherine Baicker to its board of directors.

She will serve on the public policy and compliance committee for the pharmaceutical company, whose CEO John Lechleiter hailed her as a leading researcher in the fields of health economics, public economics and labour economics.

“As a valued advisor to numerous healthcare-related commissions and committees, her expertise in healthcare policy and healthcare delivery is recognised by both academia and government. In a rapidly-changing healthcare landscape, Kate's insights will be invaluable as we work to sustain an environment that is conducive to medical innovation while still ensuring access to affordable, quality healthcare," he added.

Between 2005 and 2007, Baicker was a member of the President's Council of Economic Advisers, and currently serves as a research associate at the National Bureau of Economic Research and an elected member of the Institute of Medicine.

She also sits on the editorial boards of Health Affairs, the Journal of Health Economics, and the Forum for Health Economics and Policy.


13th December 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...
reaching HCPs during pandemic
Reaching patients and HCPs during the pandemic
COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...

Infographics